Research Papers:

PRKAR2B plays an oncogenic role in the castration-resistant prostate cancer

Jianjun Sha, Wei Xue, Baijun Dong, Jiahua Pan, Xiaorong WU, Dong Li, Dongming Liu and Yiran Huang _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:6114-6129. https://doi.org/10.18632/oncotarget.14044

Metrics: PDF 2257 views  |   HTML 2391 views  |   ?  


Jianjun Sha1,2,*, Wei Xue1,*, Baijun Dong1, Jiahua Pan1, Xiaorong WU1, Dong Li1, Dongming Liu1, Yiran Huang1,2

1Department of Urology, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

2School of Biomedical Engineering, Shanghai Jiaotong University, Shanghai, People’s Republic of China

*Co-first authors

Correspondence to:

Yiran Huang, email: [email protected]

Keywords: PRKAR2B, castration resistant, prostate cancer, CRPC, cell cycle

Received: July 11, 2016     Accepted: December 13, 2016     Published: December 20, 2016


Castration-resistant prostate cancer (CRPC) is an advanced form of prostate cancer. Despite some progresses have been made, the mechanism of CRPC development is still largely unknown, including the genes involved in its development have not been well defined. Here, we identifiedPRKAR2B to be a gene over-expressingin castration-resistant prostate cancer by analyzing the different online databases. Followed functional validation experiments showed that PRKAR2B promoted CRPC cell proliferation and invasion, and inhibited CRPC cell apoptosis. Whole genome transcriptome and GO enrichment analyses of the knock-down of PRKAR2B in CRPC cells showed that PRKAR2B mainly accelerated cell cycle biological process and modulated multiple cell cycle genes, such as CCNB1, MCM2, PLK1 and AURKB. Our study firstly identified PRKAR2B as a novel oncogenic gene involved in CRPC development and suggested it is a promising target for the future investigation and the treatment of CRPC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14044